AMDL, Inc., Retains Trent & Company
March 20 2005 - 10:00AM
PR Newswire (US)
AMDL, Inc., Retains Trent & Company TUSTIN, Calif., March 20
/PRNewswire/ -- AMDL, Inc. (AMEX:ADL), a developer and marketer of
tests for the early detection of cancer and other serious diseases,
today announced that it has retained Trent & Company, as its
public relations counsel. Gary L. Dreher, president and CEO of
AMDL, Inc., said, "We are pleased that Trent & Company will be
helping us communicate, inform and educate the medical and patient
community and news media regarding the Company's proprietary
products." AMDL recently announced that its consultant, Diagnostic
Oncology Clinical Research Organization (DOCRO), had submitted to
the U.S. Food and Drug Administration, on behalf of AMDL,
additional data in connection with the new application for 510(k)
clearance to market AMDL's DR-70(R) test in conjunction with CEA as
an aid in monitoring patients previously diagnosed with progressing
colorectal cancer. Specifically, DOCRO submitted data showing that
by using DR-70(R) in conjunction with the CEA test, which is the
standard test for this disease, there is a significant positive
gain in sensitivity of 24% for monitoring the progression of the
clinical disease status in previously diagnosed colorectal cancer
patients as compared to using the CEA test by itself. The CEA
(carcinoembryonic antigen) test has sensitivity that varies from 40
to 70 percent, according to published literature. "We are so
pleased to be working with AMDL on this significant medical
advancement," said Nancy Trent, the president of Trent &
Company. "Monitoring colon cancer is crucial during treatment and
remission, and DR-70 provides patients with an accurate way to
monitor the disease." About AMDL AMDL, Inc. (AMEX:ADL),
headquartered in Tustin, California, is a theranostics company,
involved in the detection and treatment of the same disease,
cancer. AMDL is the inventor, developer and worldwide marketer
through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 13 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdlcorporate.com/ . Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. EDITOR'S NOTE: To obtain more information about DR-70 or
to speak with Gary Dreher, CEO of AMDL, Inc., please contact Walter
Sperr or Pamela Wadler at +1-212-966-0024 DATASOURCE: Trent &
Company CONTACT: Walter Sperr or Pamela Wadler, +1-212-966-0024,
both of Trent & Company Web site:
http://www.trentandcompany.com/ http://www.amdlcorporate.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024